Filtered By:
Cancer: Lung Cancer
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 38250 results found since Jan 2013.
ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC
CONCLUSIONS: ATM mutations define a distinct subset of NSCLC associated with KRAS mutations, increased TMB, decreased TP53 and EGFR co-occurrence, and potential increased sensitivity to ICIs in the context of DNA-damaging chemotherapy.PMID:37733794 | DOI:10.1158/1078-0432.CCR-23-1122
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Natalie I Vokes Ana Galan Cobo Margarita Fernandez-Chas David Molkentine Santiago Trevi ño Vitaly Druker Yu Qian Sonia Patel Stephanie Schmidt Lingzhi Hong Jeff Lewis Waree Rinsurongkawong Vadeerat Rinsurongkawong J Jack Lee Marcelo V Negrao Don L Gibbon Source Type: research
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
CONCLUSIONS: Cumulatively, these results support the combination of ramucirumab plus docetaxel as an effective and safe subsequent therapy for the treatment of patients with metastatic NSCLC with disease progression irrespective of previous ICI treatment.PMID:37731641 | PMC:PMC10507469 | DOI:10.3389/fonc.2023.1247879
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Edward B Garon Carla Visseren-Grul Maria Teresa Rizzo Tarun Puri Suresh Chenji Martin Reck Source Type: research
Effectiveness and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis
CONCLUSION: SFI combined with PBC for the treatment of advanced NSCLC improved the ORR, DCR, and quality of life, and reduced the incidence of myelosuppression and gastrointestinal adverse reactions. However, considering the limitations of existing evidence, further verification using high-quality RCTs is required.SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/inplasy-2022-7-0026, identifier INPLASY202270026.PMID:37731634 | PMC:PMC10507621 | DOI:10.3389/fonc.2023.1198768
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Chenxi Qiao Shuaihang Hu Dandan Wang Kangdi Cao Zhuo Wang Xinyan Wang Xiumei Ma Zheng Li Wei Hou Source Type: research
Down-regulation of interleukin-2 predicts poor prognosis and associated with immune escape in lung adenocarcinoma
Conclusion: Our results indicate that down-regulation of IL2 predicts poor prognosis and is associated with immune escape in LUAD, and IL2 could serve as a potential novel prognostic biomarker of LUAD.PMID:37731383 | DOI:10.1177/03946320231202748
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Yongwang Hou Baoli Xiang Zhicong Yang Jiangmin Liu Dandan Xu Lina Geng Minghua Zhan Yuhuan Xu Bin Zhang Source Type: research
Chronic Respiratory Diseases as a Risk Factor for Herpes Zoster Infection
CONCLUSIONS: In a standard clinical practice setting, the most prevalent respiratory diseases (asthma, COPD and lung cancer) are related to a higher risk of HZ and PHN. These data are fundamental to assess the potential impact of vaccination in this population.PMID:37734964 | DOI:10.1016/j.arbres.2023.08.010
Source: Archivos de Bronconeumologia - September 21, 2023 Category: Respiratory Medicine Authors: Diego Morena Sara Lumbreras Jos é Miguel Rodríguez Carolina Campos Mar ía Castillo Mar ía Benavent Jos é Luis Izquierdo Source Type: research
A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer
CONCLUSIONS: Although the preventive effect of lafutidine on CIPN could not be demonstrated statistically, lafutidine FACT/GOG-Ntx scores showed a trend toward decreased neurotoxicity as chemotherapy proceeded. More reliable studies using lafutidine on the prevention of CIPN should be conducted.TRIAL REGISTRATION: Japan Registry of Clinical Trials identifier: jRCTs021200031.PMID:37731302 | DOI:10.21037/apm-23-90
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Katsuya Cho Hirotaka Saikawa Tatsuya Hashimoto Hiroshi Katagiri Yoshihiro Owada Kazuhiro Yakuwa Itaru Fujimura Yu Utsumi Masachika Akiyama Hiromi Nagashima Fumiaki Takahashi Makoto Maemondo Source Type: research
Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum
Clin Lung Cancer. 2023 Aug 30:S1525-7304(23)00181-X. doi: 10.1016/j.cllc.2023.08.016. Online ahead of print.NO ABSTRACTPMID:37734987 | DOI:10.1016/j.cllc.2023.08.016
Source: Clinical Lung Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Tilmann Bochtler Petros Christopoulos Kai Schlamp Frank Winkler Alwin Kr ämer Source Type: research
ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC
CONCLUSIONS: ATM mutations define a distinct subset of NSCLC associated with KRAS mutations, increased TMB, decreased TP53 and EGFR co-occurrence, and potential increased sensitivity to ICIs in the context of DNA-damaging chemotherapy.PMID:37733794 | DOI:10.1158/1078-0432.CCR-23-1122
Source: Clinical Lung Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Natalie I Vokes Ana Galan Cobo Margarita Fernandez-Chas David Molkentine Santiago Trevi ño Vitaly Druker Yu Qian Sonia Patel Stephanie Schmidt Lingzhi Hong Jeff Lewis Waree Rinsurongkawong Vadeerat Rinsurongkawong J Jack Lee Marcelo V Negrao Don L Gibbon Source Type: research
Long non-coding RNAs in non-small cell lung cancer: Implications for preventing therapeutic resistance
Biochim Biophys Acta Rev Cancer. 2023 Sep 19:188982. doi: 10.1016/j.bbcan.2023.188982. Online ahead of print.ABSTRACTLung cancer has the highest mortality and morbidity rates among all cancers worldwide. Despite many complex treatment options, including radiotherapy, chemotherapy, targeted drugs, immunotherapy, and combinations of these treatments, efficacy is low in cases of resistance to therapy, metastasis, and advanced disease, contributing to low overall survival. There is a pressing need for the discovery of novel biomarkers and therapeutic targets for the early diagnosis of lung cancer and to determine the efficacy ...
Source: Biochimica et Biophysica Acta - September 21, 2023 Category: Biochemistry Authors: Wenjuan Liu Bingli Zuo Wenting Liu Yanfei Huo Nasha Zhang Ming Yang Source Type: research
Development of a high-performance label-free electrochemical immunosensor for early cancer diagnosis using anti-CEA/Ag-MOF/GO/GCE nanocomposite
Environ Res. 2023 Sep 19:117178. doi: 10.1016/j.envres.2023.117178. Online ahead of print.ABSTRACTIn order to detect carcinoembryonic antigen (CEA) as a tumor marker in lung cancer for early cancer diagnosis, this study aimed to develop a label-free electrochemical immunosensor based on the immobilization of an Anti-CEA antibody on a metal-organic framework (MOF)-graphene oxide nanocomposite modified glassy carbon electrode (Anti-CEA/Ag-MOF/GO/GCE). Ag-MOF/GO nanocomposite was prepared on the GCE surface using the ultrasonic irradiation method, and Anti-CEA antibody was subsequently immobilized on the surface. Analysis of ...
Source: Environmental Research - September 21, 2023 Category: Environmental Health Authors: Peng Huang Lingzhang Meng Jun Pang Haiting Huang Jing Ma Linlin He Parnian Amani Source Type: research
ATR activation by Cr-DNA damage is a major survival response establishing late S and G2 checkpoints after Cr(VI) exposure
Toxicol Appl Pharmacol. 2023 Sep 19:116696. doi: 10.1016/j.taap.2023.116696. Online ahead of print.ABSTRACTInhalation exposure to hexavalent chromium is known to cause lung cancer and other pulmonary toxicity. Cellular metabolism of chromium(VI) entering cells as chromate anion produces different amounts of reactive Cr(V) intermediates and finally yields Cr(III). Direct reduction of Cr(VI) by ascorbate (Asc), the dominant metabolic reaction in vivo but not in standard cell cultures, skips production of Cr(V) but still permits extensive formation of Cr-DNA damage. To understand the importance of different forms of biologica...
Source: Toxicology and Applied Pharmacology - September 21, 2023 Category: Toxicology Authors: Sophia Valiente Casey Krawic Anatoly Zhitkovich Source Type: research
Development of a high-performance label-free electrochemical immunosensor for early cancer diagnosis using anti-CEA/Ag-MOF/GO/GCE nanocomposite
Environ Res. 2023 Sep 19:117178. doi: 10.1016/j.envres.2023.117178. Online ahead of print.ABSTRACTIn order to detect carcinoembryonic antigen (CEA) as a tumor marker in lung cancer for early cancer diagnosis, this study aimed to develop a label-free electrochemical immunosensor based on the immobilization of an Anti-CEA antibody on a metal-organic framework (MOF)-graphene oxide nanocomposite modified glassy carbon electrode (Anti-CEA/Ag-MOF/GO/GCE). Ag-MOF/GO nanocomposite was prepared on the GCE surface using the ultrasonic irradiation method, and Anti-CEA antibody was subsequently immobilized on the surface. Analysis of ...
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Peng Huang Lingzhang Meng Jun Pang Haiting Huang Jing Ma Linlin He Parnian Amani Source Type: research
ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC
CONCLUSIONS: ATM mutations define a distinct subset of NSCLC associated with KRAS mutations, increased TMB, decreased TP53 and EGFR co-occurrence, and potential increased sensitivity to ICIs in the context of DNA-damaging chemotherapy.PMID:37733794 | DOI:10.1158/1078-0432.CCR-23-1122
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Natalie I Vokes Ana Galan Cobo Margarita Fernandez-Chas David Molkentine Santiago Trevi ño Vitaly Druker Yu Qian Sonia Patel Stephanie Schmidt Lingzhi Hong Jeff Lewis Waree Rinsurongkawong Vadeerat Rinsurongkawong J Jack Lee Marcelo V Negrao Don L Gibbon Source Type: research
CD4 levels and NSCLC metastasis: the benefits of maintaining moderate levels
CONCLUSIONS: A threshold effect is shown to exist between the peripheral blood CD4 and distant metastasis in NSCLC patients. It was revealed that the risk of distant metastasis is lower when CD4 is maintained between 32 and 44%, whereas low (< 32%) or high (> 44) levels of CD4 are associated with an increased risk of distant metastasis in NSCLC patients.PMID:37733240 | DOI:10.1007/s00432-023-05418-2
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Ying Bai Yafeng Liu Jing Wu Rui Miao Zhi Xu Chunxiao Hu Jiawei Zhou Jianqiang Guo Jun Xie Zilun Shi Xuansheng Ding Yingru Xing Dong Hu Source Type: research
Inhibition of PRKAA/AMPK (Ser485/491) phosphorylation by crizotinib induces cardiotoxicity via perturbing autophagosome-lysosome fusion
Autophagy. 2023 Sep 21. doi: 10.1080/15548627.2023.2259216. Online ahead of print.ABSTRACTCrizotinib, a small-molecule tyrosine kinase inhibitor targeting ALK, MET and ROS1, is the first-line drug for ALK-positive metastatic non-small cell lung cancer and is associated with severe, sometimes fatal, cases of cardiac failure, which increases the risk of mortality. However, the underlying mechanism remains unclear, which causes the lack of therapeutic strategy. We established in vitro and in vivo models for crizotinib-induced cardiotoxicity and found that crizotinib caused left ventricular dysfunction, myocardial injury and p...
Source: Autophagy - September 21, 2023 Category: Cytology Authors: Zhifei Xu Zezheng Pan Ying Jin Zizheng Gao Feng Jiang Huangxi Fu Xueqin Chen Xiaochen Zhang Hao Yan Xiaochun Yang Bo Yang Qiaojun He Peihua Luo Source Type: research
